TapImmune Announces Acquisition of Additional Technology

Company Completes Technology and IP Acquisition From The UBC Pursuant to an Option Agreement BELLEVUE, WA–(Marketwire – 08/05/09) – TapImmune Inc. (OTC.BB:TPIV – News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the acquisition of three follow-on inventions and IP relating to its key TAP technology…

Details

TapImmune Announces Corporate Restructuring

Bellevue WA – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the appointment of Dr. Glynn Wilson as TapImmune’s new Executive Chairman as part of an overall corporate restructuring plan. Dr. Wilson succeeds Alan Lindsay whom TapImmune Inc. thanks for his service…

Details

TapImmune Issued U.S. Patent Relating To Methods For Enhancing An Immune Response

Patent Strengthens Company Intellectual Property Portfolio VANCOUVER, Canada, June 30, 2008 – TapImmune Inc., (OTCBB: TPIM) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 7,378,087, entitled “Method of Enhancing an Immune Response.” The patent claims relate to methods for enhancing the immune response to tumor cells by introducing the…

Details

TapImmune Announces Execution of Exclusive Option Agreement with The University of British Columbia

VANCOUVER, BC – June 9, 2008 — TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that the company has executed an exclusive option agreement with The University of British Columbia (UBC) for three follow on technologies related to the original…

Details

Published Third Party, Independent Research Corroborates Promise of TAP Cancer Therapeutic as a Therapy for the Treatment of Cancer

VANCOUVER, BC–(MARKET WIRE)–Jun 2, 2008 — TapImmune Inc. (OTC BB:TPIM.OB – News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered…

Details

TapImmune Provides Shareholder Update and Review

Company Announces Completion of Initial Sterility Testing VANCOUVER, BC–(MARKET WIRE)–Apr 21, 2008 — TapImmune Inc. (OTC BB:TPIM.OB – News) (Frankfurt:GX1A.F – News) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development…

Details

Tapimmune Receives Notice Of Allowance For U.S. Patent Relating To Methods For Enhancing An Immune Response

VANCOUVER, Canada, January 22, 2008 – TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) announced today the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/046,542, entitled “Method of Enhancing an Immune Response.” The patent application has allowed claims that relate to methods for enhancing the cytotoxic T-lymphocyte…

Details

Tapimmune Retains ROI Group as Investor Relations Counsel

VANCOUVER, BC – January 16, 2008 — TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced it has retained ROI Group LLC as investor relations counsel. “TapImmune is rapidly moving forward on managements strategies to take our therapeutic TAP vaccine into…

Details

TapImmune Inc. Announces Granting of U.S. Pat. Appln No. 10/046,542 Petition to Revive and Secures Bridge Financing

VANCOUVER, Canada, – TapImmune Inc., (OTCBB: TPIM) (the “Company”) a biotechnology specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced the USPTO has granted its petition to revive the U.S. Pat. Appln No. 10/046,542. This is a key patent application for the Company, as it describes a preferable delivery…

Details

TapImmune Inc. Announces Initiation of Testing on Novel Cancer Vaccine FDA Registered Facility Begins Testing on Company’s Lead Product

VANCOUVER, Canada,– TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP based therapeutic cancer vaccine. The immunotherapy vaccine is designed…

Details